Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Administration
7 evidence topics · 4 sources
Route, frequency, and cycle length in the phase 1/2 study
Tablet formulation and administration with food in ongoing studies
Cycle length and treatment duration in OPERA-01
“All treatments are administered in 28-day cycles and continue until confirmed radiographic disease progression, intolerable toxicity, continuous dose-interruption >28 days, investigator or participant decision, or initiation of a non-protocol anti-cancer therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote